Ideaya Biosciences Inc Market Cap ($3.08 Billion)
Market Cap & Net Worth: Ideaya Biosciences Inc (IDYA)
Ideaya Biosciences Inc market cap. Ideaya Biosciences Inc (NASDAQ:IDYA) has a market capitalization of $3.08 Billion ($3.08 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4663 globally and #1627 in its home market, demonstrating a -11.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ideaya Biosciences Inc's stock price $31.96 by its total outstanding shares 96489484 (96.49 Million). Also see Ideaya Biosciences Inc (IDYA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Ideaya Biosciences Inc Market Cap History (2019–2026)
Ideaya Biosciences Inc market cap history from 2019 to 2026. Data shows growth from $723.67 Million to $3.08 Billion (15.14% CAGR). Check current stock price of Ideaya Biosciences Inc for real-time trading data and today's change.
Index Memberships
Ideaya Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.12% | #127 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #544 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.17% | #80 of 263 |
Weight: Ideaya Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ideaya Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ideaya Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IDYA net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
15.25x
Ideaya Biosciences Inc's market cap is 15.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.35 Billion | $19.54 Million | -$32.27 Million | 69.14x | N/A |
| 2021 | $2.28 Billion | $27.94 Million | -$47.53 Million | 81.64x | N/A |
| 2022 | $1.75 Billion | $50.93 Million | -$54.81 Million | 34.42x | N/A |
| 2023 | $3.43 Billion | $23.39 Million | -$112.96 Million | 146.81x | N/A |
| 2024 | $2.48 Billion | $7.00 Million | -$274.48 Million | 354.25x | N/A |
| 2025 | $3.34 Billion | $218.71 Million | -$113.70 Million | 15.25x | N/A |
Competitor Companies of IDYA by Market Capitalization
Companies near Ideaya Biosciences Inc in the global market cap rankings as of November 1, 2026. Also see IDYA total asset value for a full breakdown of the balance sheet.
Key companies related to Ideaya Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ideaya Biosciences Inc (2019–2026)
Market capitalization of Ideaya Biosciences Inc from 2019 to today. Between 2019 and today, Ideaya Biosciences Inc's market cap moved from $723.67 Million to $ 3.08 Billion, with a yearly change of 15.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.08 Billion | -7.55% |
| 2025 | $3.34 Billion | +34.51% |
| 2024 | $2.48 Billion | -27.77% |
| 2023 | $3.43 Billion | +95.82% |
| 2022 | $1.75 Billion | -23.14% |
| 2021 | $2.28 Billion | +68.86% |
| 2020 | $1.35 Billion | +86.67% |
| 2019 | $723.67 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ideaya Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.08 Billion USD |
| MoneyControl | $3.08 Billion USD |
| MarketWatch | $3.08 Billion USD |
| marketcap.company | $3.08 Billion USD |
| Reuters | $3.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more